{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:40:25Z","timestamp":1768678825293,"version":"3.49.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Aim:<\/jats:title>\n            <jats:p>Chronic graft versus host disease (cGVHD) is a major cause of morbidity postallogeneic peripheral blood stem cell transplant (PBSCT). There is paucity of literature describing incidence, risk factors, characteristics, and outcome of cGVHD in children undergoing haploidentical PBSCT with post-transplant cyclophosphamide (PTCy). Here, we describe our experience from our center regarding the same.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All children who underwent haploidentical PBSCT with PTCy between January 2016 and December 2021 at our center and survived beyond day+100 post-transplant were included in this retrospective study. Conditioning regimens used were: Thiotepa-Fludarabine-Cyclophosphamide with 2\u00a0Gy single fraction total body irradiation, Thiotepa-Busulfan-Fludarabine, Fludarabine-total body irradiation and Fludarabine-Melphalan. Peripheral blood was used as stem cell source in all patients. GVHD prophylaxis was PTCy 50\u00a0mg\/kg on day +3 and +4, Mycophenolate mofetil and Calcineurin inhibitors. Clinical and laboratory data was electronically retrieved and analyzed based on National Institute of Health Consensus Criteria-2014 at regular intervals. Impact of various patient, donor, and transplant-related factors on development of cGVHD were analyzed. Incidence of relapse, event free survival (EFS) and overall survival (OS) were calculated and compared between cGVHD and no cGVHD groups. Patients with rejection were excluded from risk factor analysis for cGVHD but were considered for survival analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-one children included in this study. Median age of transplant of our cohort was 7.5 years with male:female=1.6:1. Eight patients had rejection with autologous recovery. History of acute GVHD (aGVHD) was present in 15\/51 (Grade III to IV in 7\/51). cGVHD developed in 19\/51 patients (mild-9\/51, moderate-6\/51, and severe-4\/51). Skin was the most common organ involved (100%) followed by gastrointestinal tract (47.4%), liver (36.8%), eyes (21%), lungs (21%), mouth (15.7%), and joints (5.2%). Advanced donor age (&gt;30\u00a0y) and previous aGVHD were found to be significantly associated with increased risk of developing cGVHD. At last follow-up, complete response and partial response of cGVHD was seen in 6\/19 and 4\/19 patients, respectively. Overall mortality was 15\/51 (cause of mortality was relapse of cancer 8\/15, cGVHD-3\/15, other 4\/15). EFS and OS of full cohort was 55% and 70.6%, respectively. Compared with patients without cGVHD, patients with cGVHD demonstrated a lower relapse (18.2% vs. 40%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.2333), higher EFS (68.4% vs. 53.1%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.283), and higher OS (73.7% vs. 68.8%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.708).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Incidence of cGVHD was high in children undergoing haploidentical PBSCT with PTCy. Other than PBSC graft source; donor age and previous aGVHD were the risks factors for development of cGVHD. Patients with cGVHD had lower incidence of relapse translating into better survival but this difference was not statistically significant.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002786","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T16:07:38Z","timestamp":1700496458000},"page":"e44-e50","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Incidence, Risk Factors, Characteristics, and Outcome of Chronic Graft Versus Host Disease in Children Undergoing Haploidentical Peripheral Blood Stem Cell Transplant With Post-transplant Cyclophosphamide"],"prefix":"10.1097","volume":"46","author":[{"given":"Sunisha","family":"Arora","sequence":"first","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhwanee","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Upasana","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Yadav","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem S.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Statistics, University College of Medical Sciences, Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya P.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute, Medanta The Medicity Hospital, Gurgaon, Haryana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","article-title":"Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation\u2014results from a single-center observational study","volume":"22","author":"Grube","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(95)91268-1","article-title":"Allogeneic sibling umbilical cord-blood transplantation in children with malignant and non-malignant disease","volume":"346","author":"Wagner","year":"1995","journal-title":"Lancet"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.bbmt.2007.07.009","article-title":"Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies","volume":"13","author":"Meisel","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/08880018.2014.961214","article-title":"Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies","volume":"31","author":"Sawada","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","article-title":"Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies","volume":"23","author":"Klein","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin N Am"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"667.e1","DOI":"10.1016\/j.jtct.2021.05.022","article-title":"Late-onset acute and chronic graft-versus-host disease in children: clinical features and response to therapy","volume":"27","author":"Takahashi","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"424.e1","DOI":"10.1016\/j.jtct.2021.01.016","article-title":"Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ruggeri","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200006223422501","article-title":"Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources","volume":"342","author":"Rocha","year":"2000","journal-title":"N Engl J Med"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.bbmt.2005.05.003","article-title":"Busulfan\/melphalan\/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience","volume":"11","author":"Wall","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bbmt.2020.05.021","article-title":"Incidence, risk factors, and outcomes of chronic graft-versus-host disease in pediatric patients with hematologic malignancies after T cell-replete myeloablative haploidentical hematopoietic stem cell transplantation with antithymocyte globulin\/granulocyte colony-stimulating factor","volume":"26","author":"Tang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2001-11-0059","article-title":"Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplant. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome","volume":"100","author":"Zecca","year":"2002","journal-title":"Blood"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2141.2007.06543.x","article-title":"Japan Marrow Donor Program. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program","volume":"137","author":"Ozawa","year":"2007","journal-title":"Br J Haematol"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/bmt.2010.174","article-title":"GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome","volume":"46","author":"Alsultan","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mds615","article-title":"NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia","volume":"24","author":"Terwey","year":"2013","journal-title":"Ann Oncol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1182\/bloodadvances.2023010281","article-title":"Prospective PTCTC trial of myeloablative HaploBMT with post-transplant cyclophosphamide for pediatric acute leukemias","volume":"7","author":"Fierro-Pineda","year":"2023","journal-title":"Blood Adv"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:49Z","timestamp":1754337829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002786","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"2023-02-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}